NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets open in 3 hrs 57 mins

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
42.04 +1.87 (+4.66%)
At close: 4:00PM EST
People also watch
ALKS LGND PGNX NKTR INCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 40.17
Open 0.00
Bid 31.59 x 100
Ask 0.00 x
Day's Range 38.84 - 43.44
52 Week Range 31.25 - 55.15
Volume 3,340,246
Avg. Volume 1,113,159
Market Cap 3.65B
Beta 0.63
PE Ratio (TTM) -28.93
EPS (TTM) -1.45
Earnings Date Feb 9, 2017 - Feb 13, 2017
Dividend & Yield 0.00 (0.00%)
Ex-Dividend Date N/A
1y Target Est 66.92
Trade prices are not sourced from all markets
  • CNBC yesterday

    After hours buzz: CSX, UAL, GIMO & more

    Check out Tuesday's after hours buzz: CSX, UAL, GIMO & more

  • Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down
    Investor's Business Daily yesterday

    Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down

    Neurocrine's Tourette drug failed in a trial and the FDA approved a generic narcolepsy drug rivaling Jazz, and both stocks fell late.

  • TheStreet.com 2 days ago

    Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

    The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.

  • Here Are Two Market Moving Biotech Catalysts To Watch This Week
    Insider Monkey 2 days ago

    Here Are Two Market Moving Biotech Catalysts To Watch This Week

    The biotechnology sector is in full swing for the New Year, and while the JP Morgan conference is now in the rearview mirror, there are still plenty of potential catalysts set to hit press between now and the end of January. Here are two of the releases that we are most highly anticipating, with a […]

  • Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017
    Capital Cube 8 days ago

    Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Neurocrine Biosciences, Inc. a score of 29. Our analysis is based on comparing Neurocrine Biosciences, Inc. with the following peers – Repligen Corporation, Repros Therapeutics Inc., Paratek Pharmaceuticals Inc, Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company, AbbVie, Inc., CASI Pharmaceuticals Inc, ANI Pharmaceuticals, Inc. and ... Read more (Read more...)

  • Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017
    Capital Cube 9 days ago

    Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : January 10, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Zacks Small Cap Research 13 days ago

    NBIX: AdComm Meeting for INGREZZA™ Cancelled by FDA

    On January 5, 2017, Neurocrine Biosciences, Inc. (NBIX) announced that the Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting that was originally scheduled for Feb. 16, 2017 after further review of the INGREZZA™ New Drug Application (NDA). The FDA informed the company that the Priority Review of the NDA for INGREZZA™ for the treatment of tardive dyskinesia (TD) was continuing as planned with the previously announced Prescription Drug User Fee Act (PDUFA) date of April 11, 2017. During the conference call to discuss the situation, management indicated that they have had nothing but positive interactions with the FDA up to and during review of the NDA and that they were not aware of any issues with the review of the NDA.

  • What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?
    Insider Monkey 13 days ago

    What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?

    Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just announced that that the FDA has cancelled the Psychopharmacologic Drugs Advisory Committee meeting for INGREZZA. The meeting, which was originally scheduled to take place on February 16, 2017, will now be skipped, and the drug will carry straight through to the PDUFA date, scheduled for April 11, 2017. This is […]

  • 24/7 Wall St. 13 days ago

    These 5 Biotech Stocks Could Be Big Takeover Targets in 2017

    A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.

  • Investopedia 14 days ago

    Biotech Firms Awaiting FDA Decisions In Early 2017

    Investopedia looks at biotech companies that are awaiting FDA decisions in early 2017.